SEARCH

SEARCH BY CITATION

References

  • 1
    National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: 2002–June 10–12, 2002. Hepatology 2002; 36: S320.
  • 2
    Conry-Cantilena C, VanRaden M, Gibble J, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996; 334: 16916.
  • 3
    Inglesby TV, Rai R, Astemborski J, et al. A prospective, community-based evaluation of liver enzymes in individuals with hepatitis C after drug use. Hepatology 1999; 29: 5906.
  • 4
    Nutt AK, Hassan HA, Lindsey J, Lamps LW, Raufman JP. Liver biopsy in the evaluation of patients with chronic hepatitis C who have repeatedly normal or near-normal serum alanine aminotransferase levels. Am J Med 2000; 109: 624.
  • 5
    Puoti C, Bellis L, Martellino F, et al. Chronic hepatitis C and ‘normal’ ALT levels: treat the disease not the test. J Hepatol 2005; 43: 5345.
  • 6
    Alberti A, Noventa F, Benvegnu L, Boccato S, Gatta A. Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection. Ann Intern Med 2002; 137: 9614.
  • 7
    Gholson CF, Morgan K, Catinis G, et al. Chronic hepatitis C with normal aminotransferase levels: a clinical histologic study. Am J Gastroenterol 1997; 92: 178892.
  • 8
    Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 114771.
  • 9
    National Institutes of Health. National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology 1997; 26: 2S10S.
  • 10
    Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 6969.
  • 11
    Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 3724.
  • 12
    Bayliss MS, Gandek B, Bungay KM, Sugano D, Hsu MA, Ware JE Jr. A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C. Qual Life Res 1998; 7: 3955.
  • 13
    Ware JE Jr. Hepatitis Quality of Life Questionnaire (HQLQ) Scoring Documentation. Lincoln RI: QualityMetric Incorporated, 1999.
  • 14
    Ware JE Jr, Kosinski M, Keller SD. SF-36 Physical and Mental Health Summary Scales: A User's Manual. Boston, MA, USA: Health Assessment Lab, 1994.
  • 15
    Tassopoulos NC, Vafiadis I, Tsantoulas D, et al. IFN-alpha2b monotherapy in patients with chronic hepatitis C and persistently normal or near normal aminotransferase activity: a randomized, controlled study. J Interferon Cytokine Res 2002; 22: 3659.
  • 16
    Mamori S, Suzuki F, Hosaka T, et al. Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatment. J Gastroenterol 2004; 39: 77682.
  • 17
    Shiffman ML, Stewart CA, Hofmann CM, et al. Chronic infection with hepatitis C virus in patients with elevated or persistently normal serum alanine aminotransferase levels: comparison of hepatic histology and response to interferon therapy. J Infect Dis 2000; 182: 1595601.
  • 18
    Rossini A, Ravaggi A, Biasi L, et al. Virological response to interferon treatment in hepatitis C virus carriers with normal aminotransferase levels and chronic hepatitis. Hepatology 1997; 26: 10127.
  • 19
    Ohmiya M, Hayashi J, Ueno K, et al. Effectiveness of interferon treatment for patients with chronic hepatitis C virus infection and normal aminotransferase levels. Dig Dis Sci 2000; 45: 19538.
  • 20
    Srinivas D, Mani H, Crumpler CC, Van Thiel DH. Daily interferon monotherapy for chronic hepatitis C in patients with normal or near-normal serum alanine transaminase levels: a comparison of two protocols. South Med J 2005; 98: 1649.
  • 21
    Tran A, Longo F, Ouzan D, et al. Effects of 1-year interferon-alpha 2a treatment in patients with chronic hepatitis C and persistently normal transaminase activity. Scand J Gastroenterol 2000; 35: 4337.
  • 22
    Sangiovanni A, Morales R, Spinzi G, et al. Interferon alfa treatment of HCV RNA carriers with persistently normal transaminase levels: a pilot randomized controlled study. Hepatology 1998; 27: 8536.
  • 23
    Van Thiel DH, Caraceni P, Molloy PJ, et al. Chronic hepatitis C in patients with normal or near normal alanine aminotransferase levels: the role of interferon alpha 2b therapy. J Hepatol 1995; 23: 5038.
  • 24
    Serfaty L, Chazouilleres O, Pawlotsky JM, Andreani T, Pellet C, Poupon R. Interferon alfa therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity. Gastroenterology 1996; 110: 2915.
  • 25
    Silverman AL, Piquette DL, Filipiak CL, Neill JS, Bayati N, Gordon SC. Alfa interferon treatment of hepatitis C virus RNA-positive patients with normal or near-normal alanine aminotransferase levels. Am J Gastroenterol 1997; 92: 17935.
  • 26
    Sakugawa H, Nakasone H, Nakayoshi T, et al. Alanine aminotransferase (ALT) levels in a normal population and interferon therapy in chronic hepatitis C patients with normal ALT. Hepatogastroenterology 2003; 50: 1659.
  • 27
    Yagura M, Murai S, Kojima H, Tokita H, Kamitsukasa H, Harada H. Interferon treatment in patients with chronic hepatitis C with normal alanine aminotransferase activity. Hepatogastroenterology 1999; 46: 10949.
  • 28
    Orito E, Mizokami M, Suzuki K, et al. Interferon-alpha therapy for individuals with normal serum alanine aminotransferase levels before treatment. J Gastroenterol Hepatol 1997; 12: 5861.
  • 29
    Bacon BR. Treatment of patients with hepatitis C and normal serum aminotransferase levels. Hepatology 2002; 36: S17984.
  • 30
    Thevenot T, Regimbeau C, Ratziu V, Leroy V, Opolon P, Poynard T. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 update. J Viral Hepat 2001; 8: 4862.
  • 31
    Carithers RL Jr, Emerson SS. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology 1997; 26: 83S8S.
  • 32
    McHutchison JG, Poynard T. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin Liver Dis 1999; 19 (Suppl. 1): 5765.
  • 33
    Lee SS, Sherman M. Pilot study of interferon-alpha and ribavirin treatment in patients with chronic hepatitis C and normal transaminase values. J Viral Hepat 2001; 8: 2025.
  • 34
    Hasan F, Asker H, Al Khalid J, et al. Interferon-alpha in combination with ribavirin for the treatment of chronic hepatitis C in patients with persistently normal aminotransferase levels. Digestion 2002; 65: 12730.
  • 35
    Erhardt A, Behlen-Wilm U, Adams O, Donner A, Heintges T, Haussinger D. Combination treatment of IFNalpha2b and ribavirin in patients with chronic hepatitis C and persistently normal ALTs. Dig Dis Sci 2003; 48: 9215.
  • 36
    Hui CK, Monto A, Belaye T, Lau E, Wright TL. Outcomes of interferon alpha and ribavirin treatment for chronic hepatitis C in patients with normal serum aminotransaminases. Gut 2003; 52: 16448.
  • 37
    Mangia A, Spinzi G, Vuturo O, et al. Viral clearance in HCV viraemic patients with normal alanine aminotransferase after combination therapy: a controlled, open-labelled study. Aliment Pharmacol Ther 2004; 19: 3317.
  • 38
    Jacobson IM, Ahmed F, Russo MW, et al. Interferon alfa-2b and ribavirin for patients with chronic hepatitis C and normal ALT. Am J Gastroenterol 2004; 99: 17005.
    Direct Link:
  • 39
    McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 148592.
  • 40
    Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004; 350: 226571.
  • 41
    Howell C, Jeffers L, Hoofnagle JH. Hepatitis C in African Americans: summary of a workshop. Gastroenterology 2000; 119: 138596.
  • 42
    Zeuzem S, Diago M, Gane E, et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004; 127: 172432.
  • 43
    Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology 2005; 41: 790800.